Groundbreaking studies indicate Semaglutide and Tirzepatide may reduce alcohol consumption in individuals with obesity

The impact of semaglutide and tirzepatide and glucagon-like peptide-1 receptor agonist medications on alcohol consumption.

FibroGen’s pamrevlumab disappointing results marks second failure in a row – Pharmaceutical Technology

FribroGen received $150m in non-dilutive funding from Morgan Stanley Tactical Value for pamrevlumab commercialisation. Image Credit: fran_kie / Shutterstock. FibroGen’s lead candidate pamrevlumab failed to

August 30, 2023

Ancient population bottleneck revealed by new genomic study

Between 800,000 and 900,000 years ago, the population of human ancestors crashed, according to a new genomic model by Wangjie Hu and colleagues.

September 1, 2023

MSOs Post New Highs

You’re reading this week’s edition of the New Cannabis Ventures weekly newsletter, which we have been publishing since October 2015. The newsletter includes unique insight

January 27, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.